References
- Stonebraker JS, Bolton-Maggs PHB, Michael Soucie J, et al. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia. 2012;18:e91–94.
- Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of haemophilia. Haemophilia. 2013;19:e1–e47.
- Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388:187–197.
- The Australian Haemophilia Centre Directors’ Organisation. Guidelines for the management of haemophilia in Australia. 20 July 2016. Available at: https://www.blood.gov.au/system/files/HaemophiliaGuidelines-interactive-updated-260317v2.pdf Accessed 2017 Aug 6
- Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. 2008;14:671–684.
- MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders (number 249). 19 May, 2017. Available at: https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-Concerning-Products-Licensed-for-the-Treatment-of-Hemophilia-and-Other-Bleeding-Disorders Accessed 2017 Aug 6
- Valentino LA, Rusen L, Elezovic I, et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B patients. Haemophilia. 2014;20:398–406.
- Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia. 2016;22:381–388.
- Franchini M, Mannucci PM. The safety of pharmacologic options for the treatment of persons with haemophilia. Expert Opin Drug Safety. 2016;15:1391–1400.
- Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm TM4). Thromb Res. 2016;141:69–76.
- FDA. Approval letter – benefix. 11 February, 1997. Available at: https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm057039.htm Accessed 2017 Aug 6
- EMA. BeneFIX (nonacog alfa) EPAR summary for the public. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000139/WC500020384.pdf Accessed August 6, 2017.
- FDA. Approval letter – rixubis. 26 June, 2013. Available at: https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm358877.htm Accessed 2017 Aug 6
- FDA. Approval letter – rixubis. 12 September, 2014. Available at: https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm414489.htm Accessed 2017 Aug 6
- EMA. Rixubis summary of opinion. 23 October, 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003771/WC500176348.pdf Accessed 2017 Aug 6
- FDA. Approval Letter – ixinity. 14 May, 2015. Available at: https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm445097.pdf. Accessed 2017 Aug 6
- Monroe DM, Jenny RJ, Van Cott KE, et al. Characterization of IXINITY (Trenonacog Alfa), a recombinant factor IX with primary sequence corresponding to the threonine-148 polymorph. Adv in Haem. 2016;2016:7678901.
- EMA. Withdrawal assessment report. Ixinity (formerly IB1001). 20 September, 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2013/09/WC500149845.pdf. Accessed 2017 Aug 6
- Ixinity (trenonacog alfa) prescribing information. Aptevo. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM445106.pdf. Accessed August 6, 2017.
- Wallmark A, Kunkel G, Mouhli H, et al. Population genetics of the Malmö polymorphism of coagulation factor IX. Hum Hered. 1986;37:411–416.
- Drobic B, Hua Y, Babinchak T, et al. Evaluation of host cell protein immunogenicity of a polished recombinant factor IX investigational product, IB1001 in previously treated patients with hemophilia B. J Thromb Haemost. 2015;13(Suppl. 2):323.
- Cheung P, Emanuel A, Heward J, et al. Reduced immunogenic response to residual CHO cell protein in recombinant factor IX (IB1001) drug product in normal health rabbits. Haemophilia. 2016;22:e208–e244.
- ClinicalTrials.gov. Study of recombinant factor IX product, IB1001, in subjects with hemophilia B. Available at: https://clinicaltrials.gov/ct2/show/study/NCT00768287. Accessed August 6, 2017.
- FDA. Summary basis for regulatory action – ixinity. 27 April, 2015. Available at: https://archive-it.org/collections/7993?q=IB1001&show=ArchivedPages&hitsPerDupe=0&go=Search+the+Archive Accessed 2017 Aug 6
- Collins PW, Quon DVK, Makris M, et al. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2017;1–9.10.1111/hae.13324
- Martinowitz U, Shapiro A, Quon DV, et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia. 2012;18:881–887.
- Leisner R, Fritz R, MacPherson B, et al. The safety and efficacy of IB1001 in previously treated children 12 years of age or younger with haemophilia. Res Practice Thromb Haemost. 2017;1(Suppl S1):779.
- FDA. Statistical review and evaluation, final – IXNITY. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM448429.pdf. Accessed August 6, 2017.
- ClinicalTrials.gov. Study of recombinant factor IX product, IB1001, in previously treated pediatric subjects with hemophilia B. Available at: https://clinicaltrials.gov/ct2/show/NCT01271868. Accessed August 6, 2017.
- Schaaf D, Eisenfeld A, Macpherson B. The safety and efficacy of IB1001 in children with haemophilia B: a pooled analysis. Haemophilia. 2017;23(Suppl. 3):38.
- Hofbauer EJ, Kepa S, Schemper M, et al. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate haemophilia A without inhibitors. Thromb Haemost. 2016;128:293–296.
- Windyga J, Lissitchkov T, Stasyshyn O, et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. Haemophilia. 2014;20:15–24.
- Ewenstein BM, Joist JH, Shapiro AD, et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe haemophilia B. Transfusion. 2002;42:190–197.
- Björkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia. 2013;19:753–757.
- Guh S, Grosse D, McAlister S, et al. Healthcare expenditures for males with haemophilia and employer-sponsored insu-rance in the United States, 2008. Haemophilia. 2012;18:268–275.
- Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in haemophilia A or B with RNAi therapy. N Eng J Med. 2017;377:819–828.